Biogen (BIIB) Cash & Equivalents Growth (1y) (2010 - 2026)
Biogen (BIIB) Cash & Equivalents Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 9.93% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 1.58% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -14.46% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 14.42% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -30.58% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 74.25% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -38.20% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -40.42% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -13.23% |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | -53.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -53.42% |
| Mar 31, 2026 | 30.19% |
| Dec 31, 2025 | 26.67% |
| Sep 30, 2025 | 127.33% |
| Jun 30, 2025 | 44.52% |
| Mar 31, 2025 | 141.84% |
| Dec 31, 2024 | 126.21% |
| Sep 30, 2024 | -25.73% |
| Jun 30, 2024 | -27.08% |
| Mar 31, 2024 | -62.93% |
| Dec 31, 2023 | -69.29% |
| Sep 30, 2023 | -37.75% |
| Jun 30, 2023 | -1.09% |
| Mar 31, 2023 | 65.68% |
| Dec 31, 2022 | 51.20% |
| Sep 30, 2022 | 138.40% |
| Jun 30, 2022 | 51.93% |
| Mar 31, 2022 | 43.68% |
| Dec 31, 2021 | 69.88% |
| Sep 30, 2021 | -30.70% |